FDA-cleared profile

LiverMultiScan (v6.0)

Perspectum, Ltd.

LiverMultiScan v6.0 is MR diagnostic software for non-invasive liver-health assessment that generates, displays, and supports review of MR data and quantitative cT1, PDFF, and LIC metrics or composite images for trained healthcare-professional interpretation.

Evidence status: each field shows source quality, applicability, and review date. Research pending, information not established in reviewed sources, and vendor documentation pending are distinct outcomes.

Clinical fit

What this tool is for

Start with the authorized purpose, then verify how it fits your service line and reading workflow.

Exact purpose
LiverMultiScan v6.0 is MR diagnostic software for non-invasive liver-health assessment that generates, displays, and supports review of MR data and quantitative cT1, PDFF, and LIC metrics or composite images for trained healthcare-professional interpretation.
FDA source Exact FDA submission Checked 2026-09-04
Intended users
Trained radiologists, hepatologists, and other healthcare professionals interpreting abdominal MR.
FDA source Exact FDA submission Checked 2026-09-04
Care setting and population
Abdominal and liver-MR imaging services in hospitals and qualified imaging facilities.
FDA source Exact FDA submission Checked 2026-09-04
Workflow role
Standalone MR post-processing and quantitative liver-health assessment support.
FDA source Exact FDA submission Checked 2026-09-04
Required input
Supported abdominal MR data, including the labeled sequences for cT1, PDFF, and LIC analysis.
FDA source Exact FDA submission Checked 2026-09-04
Output and human action
Quantitative liver metrics, composite images, and review displays for trained healthcare-professional interpretation.
FDA source Exact FDA submission Checked 2026-09-04
Limitations
Metrics require supported acquisition, segmentation, quality control, and professional interpretation. LiverMultiScan is an aid to clinical decisions and does not replace a complete clinical assessment.
FDA source Exact FDA submission Checked 2026-09-04

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K253413
FDA source Exact FDA submission Checked 2026-08-31
Modality
MRI
FDA source Exact FDA submission Checked 2026-09-04
Anatomy
Liver
FDA source Exact FDA submission Checked 2026-09-04
Clearance type
510(k)
FDA source Exact FDA submission Checked 2026-08-31
Decision date
2026-03-09
FDA source Exact FDA submission Checked 2026-08-31
FDA status
FDA-cleared
FDA source Exact FDA submission Checked 2026-08-31

Implementation

Questions for IT, informatics, and operations

Use these fields to structure a vendor demo, security review, and implementation estimate.

Integration
The FDA package describes standalone MR post-processing and quantitative outputs; exact DICOM routing, PACS return, and local reporting interfaces require testing.
FDA source Exact FDA submission Checked 2026-09-04
Deployment and data flow
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-04

The exact installed deployment, hosting, service, and operational boundary is not established by the reviewed public FDA material.

Security and privacy
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-04

The FDA decision material does not establish the complete security posture for the exact product and deployment. Obtain architecture, identity, audit, encryption, retention, support-access, vulnerability-management, and incident-response evidence.

Training and support
Only trained radiologists, hepatologists, and other healthcare professionals interpreting abdominal mr. should operate or interpret this product. Local onboarding must cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
FDA source Exact FDA submission Checked 2026-09-04
Monitoring and change control
Monitor K253413 by exact software, hardware, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Metrics require supported acquisition, segmentation, quality control, and professional interpretation. LiverMultiScan is an aid to clinical decisions and does not replace a complete clinical assessment.
FDA source Exact FDA submission Checked 2026-09-04

Release and scope verification

Map the installed product, build, options, population, anatomy, inputs, outputs, and enabled functions to K253413 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared release includes them.

Deployment boundary

The exact installed deployment, hosting, service, security, and operational boundary remains unverified and requires site-specific confirmation.

exact submission · checked 2026-09-04

FDA-described deployment details do not establish current hosting contracts, security controls, uptime, or local qualification.

Interoperability acceptance

The FDA package describes standalone MR post-processing and quantitative outputs; exact DICOM routing, PACS return, and local reporting interfaces require testing.

exact submission · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Metrics require supported acquisition, segmentation, quality control, and professional interpretation. LiverMultiScan is an aid to clinical decisions and does not replace a complete clinical assessment.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-04

No exact-product price or product-specific reimbursement was established in the reviewed public material.

Lifecycle monitoring

Monitor K253413 by exact software, hardware, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Metrics require supported acquisition, segmentation, quality control, and professional interpretation. LiverMultiScan is an aid to clinical decisions and does not replace a complete clinical assessment.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version.

Evidence summary
The FDA package documents non-invasive liver-health assessment and quantitative MR output for v6.0; no exact-version independent outcome claim was promoted.
FDA source Exact FDA submission Checked 2026-09-04
Reported sensitivity
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-04

No single product-level sensitivity value was promoted because the reviewed FDA material is workflow, module, sequence, or population specific.

Reported specificity
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-04

No single product-level specificity value was promoted because the reviewed FDA material is workflow, module, sequence, or population specific.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K253413 FDA evidence package for LiverMultiScan (v6.0)

FDA 510(k) verification and validation evidence described in the exact submission · Liver

exact submission · Tested version: LiverMultiScan v6.0 · Sponsor or vendor study

K253413

Manufacturer evidence submitted for the exact FDA decision. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.

Economics and lifecycle

Budget and ongoing governance

These are common procurement questions; unknown values remain visible until a source supports them.

Pricing and total cost
Not established in reviewed sources
Reviewed sources checked Exact FDA submission Checked 2026-09-04

No public list price for the exact cleared product version was established. Obtain a written quote separating license, implementation, interfaces, compute, storage, training, support, upgrades, renewal, and exit costs.

Reimbursement and coding
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging or clinical service line and verify payer, site-of-service, coding, and coverage assumptions independently.
Public source Not applicable Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed CMS material

Centers for Medicare & Medicaid Services · United States

This is not a product-specific reimbursement determination. Verify payer, site-of-service, coding, and coverage assumptions independently.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no candidate record for K253413; no exact native submission identifier match was found.
Public source Exact FDA submission Checked 2026-09-04

Buyer worksheet

Open questions to take to the vendor

Open evaluation checklist

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-04Last searched
25Fields reviewed
10Source classes checked
20Reviewed PubMed leads
10Reviewed trial leads
0Unreviewed FDA recall leads

Screened 20 PubMed titles and 10 trial records. Several identify LiverMultiScan or Perspectum product-family use, but none establishes LiverMultiScan v6.0 or K253413 as the tested release; all 30 remain quarantined. The current discovery snapshot contains 20 PubMed and 10 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, acr ai central product, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Sources

Source ledger

Sources accessed through 2026-09-04.

Alternatives

Related tools to compare

FDA-cleared K231459

HepaFatSmart (V2.0.0)

Resonance Health Analysis Services Pty Ltd

Provide quantitative volumetric liver fat fraction, proton-density fat fraction, and steatosis grading to support clinical diagnosis and subsequent management decisions for...

Modality
MRI
Anatomy
Liver
Decision
2023-06-20
FDA-cleared K213776

LiverSmart

Resonance Health Analysis Services Pty Ltd

LiverSmart is indicated to -For Liver Iron Concentration:(i) measure liver iron concentration in individuals with confirmed or suspected systemic iron overload;(ii) monitor liver...

Modality
MRI
Anatomy
Liver
Decision
2021-12-29